Six-month analysis of tisagenlecleucel in stubborn form of lymphoma shows sustained responses
Stephen J. Schuster
Panel discussion on the treatment of adolescent and young adult lymphoma patients
Catherine Bollard et al.
Panel discussion on large cell lymphomas: subtypes, patient selection and mutations
Andrew Zelenetz et al.
The potential clinical implications of targeted therapies for DLBCL and why the situation is complex
Upcoming trials for DLBCL: R-CHOP with acalabrutinib and obinutuzumab with checkpoint inhibitor
Targeted molecular signatures of DLBCL and upcoming CheckMate 647 trial for PCNSL and PTL
The importance of diagnosing DLBCL on a molecular level and how it will improve treatment